JUXTAPID

Drug Aegerion Pharmaceuticals, Inc.
Total Payments
$19.8M
Transactions
2,779
Doctors
1,747
Companies
3

Payment Trends by Year

Year Amount Transactions Doctors
2024 $1.8M 237 167
2021 $2.1M 782 650
2020 $2.3M 237 116
2019 $7.7M 377 330
2018 $2.7M 439 345
2017 $3.2M 707 562

Payments by Nature

Nature of Payment Amount Transactions Share
Royalty or License $19.5M 27 98.3%
Unspecified $156,093 266 0.8%
Consulting Fee $54,500 15 0.3%
Food and Beverage $41,104 2,364 0.2%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,713 43 0.2%
Honoraria $32,340 19 0.2%
Travel and Lodging $9,612 40 0.0%
Space rental or facility fees (teaching hospital only) $6,000 3 0.0%
Grant $508.00 1 0.0%
Education $10.00 1 0.0%

Payments by Type

General
$19.6M
2,513 transactions
Research
$156,093
266 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
LOWER: Lomitapide Observational Worldwide Evaluation Registry Amryt Pharma Holdings Ltd $104,260 8
LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) Chiesi USA, Inc. $28,166 7
Aegerion Lomitapide ClinDevOps Aegerion Pharmaceuticals, Inc. $23,667 6

Top Doctors Receiving Payments for JUXTAPID — Page 68

Doctor Specialty Location Total Records
Alain Taylon Omaha, NE $11.33 1
, M.D Cardiovascular Disease Council Bluffs, IA $11.32 1
, MD Pediatrics Rome, GA $11.30 1
, PA-C Physician Assistant Rome, GA $11.30 1
, ACNPC-AG Nurse Practitioner Rome, GA $11.30 1
, M.D Cardiovascular Disease Enid, OK $11.29 1
, DO Cardiovascular Disease Sumter, SC $11.28 1
, D.O Student in an Organized Health Care Education/Training Program Dayton, OH $11.28 1
, M.D Cardiovascular Disease Florence, SC $11.28 1
, MD Cardiovascular Disease Fayetteville, NC $11.27 1
, MD Interventional Cardiology Hannibal, MO $11.26 1
, MD Endocrinology, Diabetes & Metabolism Boston, MA $11.25 1
, M.D Internal Medicine Port Charlotte, FL $11.25 1
, MD Endocrinology, Diabetes & Metabolism Lubbock, TX $11.24 1
, MD Cardiovascular Disease Roanoke, VA $11.23 1
, M.D Cardiovascular Disease Grandville, MI $11.22 1
, MD FACC Cardiovascular Disease Cleveland, OH $11.22 1
, DO Cardiovascular Disease Peoria, AZ $11.20 1
, MD PHD Endocrinology, Diabetes & Metabolism Amarillo, TX $11.18 1
, M.D Cardiovascular Disease Council Bluffs, IA $11.17 1
, MD Cardiovascular Disease Bedford, TX $11.17 1
, M.D Cardiovascular Disease Portsmouth, VA $11.15 1
, M.D Cardiovascular Disease Anaheim, CA $11.14 1
, M.D Cardiovascular Disease Frederick, MD $11.13 1
, M.D Cardiovascular Disease Frederick, MD $11.13 1

About JUXTAPID

JUXTAPID is a drug associated with $19.8M in payments to 1,747 healthcare providers, recorded across 2,779 transactions in the CMS Open Payments database. The primary manufacturer is Aegerion Pharmaceuticals, Inc..

Payment data is available from 2017 to 2024. In 2024, $1.8M was paid across 237 transactions to 167 doctors.

The most common payment nature for JUXTAPID is "Royalty or License" ($19.5M, 98.3% of total).

JUXTAPID is associated with 3 research studies, including "LOWER: Lomitapide Observational Worldwide Evaluation Registry" ($104,260).